Mission Therapeutics divested its kidney asset MTX652 to Dimerix in a deal worth up to $292 million, redirecting resources toward its USP30 inhibitor Parkinson’s program. Mission will receive $5 million upfront, plus $47 million tied to clinical milestones and additional payments contingent on regulatory approval and sales. MTX652—renamed internally as DMX-652—targets USP30, a mitochondrial enzyme involved in clearance of damaged mitochondria, and is designed as an oral once-daily capsule. Dimerix said the acquisition broadens its renal disease strategy across the kidney continuum, complementing its Phase III focal segmental glomerulosclerosis (FSGS) program. Mission characterized the divestment as a focused shift to accelerate development of MTX325, its lead USP30 inhibitor for Parkinson’s disease. Dimerix positioned MTX652 as a differentiated, Phase II-ready program in acute kidney disease. The transaction adds a new mechanism-driven renal candidate to Dimerix’s portfolio while sharpening Mission’s development focus around USP30 biology across neurology and mitochondrial quality control.